


PKD International

Global alliance for polycystic kidney disease



Growing International Community & Strategic Priorities

PKD International: Global Growth

PKD Foundation of Mexico new member

Supporting PKD platforms in countries without patient organisations

Strategic Priorities & Advocacy

- **April** – Mental Health Toolkit (Rare Diseases); ADPKD Care Pathway (EURORDIS); Jardin Project
- **May** – EURORDIS Members Meeting; ERKNet Annual Meeting; Launch of ARTYCYST (Open Science & ADPKD)
- **June** – ERA Congress
- **July–August** – Ongoing ADPKD Care Pathway development (with ERKNet & EURORDIS)
- **September** – XX Anniversary AIRP; TheRaCil Annual Meeting/ PELSI Board.
- **November** – ERA Science

Partnership Research and Looking ahead

Industry collaboration currently in progress or in discussion:

GSK, Novartis, OTSUKA, VERTEX

Studies & Projects Supported:

- **IMPEDE** (Metformin, Phase III, AKTN) – Australian-led global study 1,174 participants worldwide
- **STOP-PKD** (SGLT2 inhibitors, University of Cologne) – 420 patients in DE/NL/ES/AT
- **ARTICYST** (University of Cologne) – OSCAR Consortium. Predicting outcomes in ADPKD

Looking Ahead:

- Growing role of patient voice in upcoming studies (Advisory Boards)
- 2026 Goal – Hosting a PKD International Members Meeting
 - Bringing global associations together
 - Listening to patients' needs & ideas
 - Strengthening advocacy & research impact

Thank you

